Dr. Sondak on Ipilimumab in Melanoma
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
Currently, there are a number of studies that are looking at ipilimumab in the adjuvant setting in stage III melanoma. Sondak says that the results of some of these studies are not yet available, but there have been a fair amount of toxicity when ipilimumab is given at the higher dose (10 mg/kg).
Sondak believes that ipilimumab should not be used in the adjuvant setting outside of a clinical study.